Furthermore, PPARg ligands have been shown to inhibit tumor growth and progression in preclinical models of lung cancer, by modulating various cellular processes in cancer cells, stromal cells and tumor microenvironment, through PPARg crosstalk with other signaling pathways. This evidence concerns the gene PPARG and lung carcinoma.